Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Download
Standard view
Full view
of .
Save to My Library
Look up keyword
Like this
2Activity
0 of .
Results for:
No results containing your search query
P. 1
Russia Pharmaceutical Market Overview Pharma Companies Target Russia Despite the Challenges It Presents

Russia Pharmaceutical Market Overview Pharma Companies Target Russia Despite the Challenges It Presents

Ratings: (0)|Views: 248 |Likes:
Aarkstore Enterprise specialize in providing online business market information. We have vast database on market research reports, company financials, company profiles, SWOT analysis, company report, company statistics, strategy review, industry report, industry research to provide excellent and innovative service to our report buyers.
Aarkstore Enterprise specialize in providing online business market information. We have vast database on market research reports, company financials, company profiles, SWOT analysis, company report, company statistics, strategy review, industry report, industry research to provide excellent and innovative service to our report buyers.

More info:

Categories:Business/Law
Published by: Aarkstore Enterprise on Feb 23, 2011
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as DOC, PDF, TXT or read online from Scribd
See more
See less

11/07/2013

pdf

text

original

 
Russia Pharmaceutical Market Overview Pharma companies target Russiadespite the challenges it presents
The Russian pharmaceutical market generated $10.1 billion in sales in 2009, growing by14.5% between 2008 and 2009. Key growth drivers include a preference for foreigndrugs rather than domestically manufactured products. The government has alsodesignated healthcare a strategic priority for the countrys future development which isexpected to stimulate Russias pharmaceutical market.Scope*Overview of socioeconomic and demographic trends, healthcare system, regulation,pricing and reimbursement and intellectual property in Russia*Assesses the size of the Russian pharmaceutical market by prescribing setting, therapyarea, leading brands and by leading companies*Examines the Russian generics and biosimilars landscape in terms of regulatory issues,level of penetration, key players and degree of brand erosion*Quantifies the R&D and manufacturing infrastructure for the leading pharmaceuticalcompanies, including key metrics and domestic M&A analysisHighlightsPrivate health expenditure accounts for one third of all healthcare costs of which 82%%is met by out-of-pocket costs due to insufficient availability of healthcare services andmedicines through the public healthcare system, as well as the widespread informalpayments for healthcare services.Registration of drugs in the Russian Federation remains a cumbersome and lengthyprocedure which lacks clarity and transparency and is subject to frequent change.Cultural and language barriers present further obstacles to foreign companies "going italone".The generics industry is complex and fragmented, dominated by a small number of international generics manufacturers. Generics produced by these companies enjoypreferential uptake driven by their perceived superiority to domestically manufacturedgenerics, with Russians choosing to pay higher prices for guaranteed quality.Reasons to Purchase*Evaluate the evolving regulatory landscape and the impact of pricing and
 
reimbursement controls on market access in Russia*Quantify the size and growth of the prescription pharmaceutical market in Russia,analyzing key therapy areas, brands and companies*Assess drivers and resistors of generic and biosimilars uptake in RussiaTable of Contents :ABOUT DATAMONITOR HEALTHCARE 2About the Healthcare Strategic Analysis Team 2Geographic specific reports: 2Global issue reports: 21. Executive Summary 3Introduction 3Strategic scoping and focus 4Key Findings 5Russia - Socio-demographic and economic analysis 5Socio-demographic trends 5Socio-economic trends 6Russia - Healthcare system and drug regulatory analysis 8Healthcare expenditure 8Healthcare insurance 9Regulatory issues 10Pricing and reimbursement issues 11Russia - Prescription pharmaceutical sales analysis 13Pharmaceutical market size 13Leading therapy areas 13Leading pharmaceutical brands 13Leading pharmaceutical companies 13Russia - Drug expiry analysis 15Generics market 15Brand erosion post patent expiry 15Biosimilars market 15Russia - Drug Industry Infrastructure analysis 17Pharmaceutical industry infrastructure overview 17Related reports 19Upcoming related reports 19Table of Contents 202. Russia - Socio-demographic and economic analysis 21Russia - Key findings 21Socio-demographic trends 21Socio-economic trends 21Russia - Demographic trends 23Population in Russia expected to decline rapidly 24Population growth rate in Russia remains low due to low birth rates 24
 
Proportion of elderly people will remain lower than in all other markets 27Life expectancy in Russia is poor and will remain so 27Russia - Disease burden in Russia 29Cardiovascular diseases and injuries are the leading cause of death and account for thehighest disease burden in Russia 31High level of preventable deaths in Russia 31HIV/AIDS presents a worrying trend in Russia 32Russia - Political climate 33The political climate in Russia has undergone recent changes 33Russia remains a centralized country with power centered on Moscow 33Russia - Economic climate 34Economy - recovery post-recession is slow but will gain momentum from 2010 34Economic growth is impacted by income inequality in Russia 35Russia - Business environment 37Although impediments to investing in Russia remain, the government is prioritizinghealthcare 37The recession has impacted unemployment levels 37Russia has a uniform tax rate 38Pharmaceuticals are subject to a reduced VAT rate of 10% 38Corruption significantly impedes foreign investment in Russia 39Local knowledge is critical for business success 393. Russia - Healthcare system and drug regulatory analysis 40Russia - Key findings 40Healthcare expenditure 40Healthcare insurance 40Regulatory issues 41Pricing and reimbursement issues 41Russia - Healthcare expenditure 43Russia - Healthcare System 45Key bodies regulating the healthcare system 45Ministry of Health and Social Development (MOH) 46Parallel healthcare system 46The Federal and Territorial Mandatory Health Insurance Fund 46Additional experts and coordinating bodies 46Primary versus hospital healthcare in Russia 47In efficiencies in the primary care system lead to over-referral, over-hospitalization andover treatment 47Significant disparities exist in the distribution of physicians and healthcare facilities 47Access to healthcare is especially problematic for the poor population... 48...but healthcare modernization plans are in place 49Project Zdorovie is focused on developing healthcare in Russia 49Local governments draft modernization plans for regions 49...but the government 2020 healthcare plan is aimed at improving healthcare 50Russia - Health insurance 51Mandatory health insurance was introduced in 1991 but has done little to improvehealthcare 51

Activity (2)

You've already reviewed this. Edit your review.
1 thousand reads
1 hundred reads

You're Reading a Free Preview

Download
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->